Postpartum Inpatient Human Papillomavirus Vaccination [ID 1670]

INTRODUCTION: The nonvalent Gardasil human papillomavirus (9vHPV) vaccine has historically been underutilized. The primary aim of the study was to see if access to the 9vHPV vaccine inpatient increases its usage. METHODS: Women ages 15–45 who received prenatal care and delivered at Sinai Hospital in Baltimore during a 6-month period were included in this study. When the 9vHPV vaccine was approved for inpatient postpartum administration, educational materials regarding its indications for use were distributed amongst a multidisciplinary team involved in prenatal and postpartum care. Chi-squared and t-test were used to compare the baseline characteristics of the groups. A covariant adjusted logistic regression model was used to evaluate factors associated with prepregnancy vaccination status. RESULTS: Two hundred twenty-eight women were enrolled in the study. Among study participants, 158 were eligible for the 9vHPV vaccine (69.2%) During the preintervention period, 69 out of 97 patients were vaccine eligible, and one patient received vaccine postpartum (1.45%). During the postintervention period, 89 out of 131 patients were eligible for the 9vHPV vaccine, and 23 patients received the vaccine postpartum (25.8%). Inpatient 9vHPV vaccination was associated with statistically significant increase in its use ( P ≤.0001). Patients receiving care at the resident clinic were significantly more likely to be vaccine eligible compared to those receiving care in the faculty clinic ( P =.0074). Older patients were also significantly more likely to be vaccine eligible ( P ≤.0001). CONCLUSIONS/IMPLICATIONS: Inpatient administration of the 9vHPV vaccine is a feasible and effective strategy to increase utilization in a low-income, urban community hospital.